---
schema_version: "secwatch.filing_event.v1"
accession: "0001641172-25-026864"
form_type: "8-K"
ticker: "AIXC"
cik: "0001460702"
company_name: "AIxCrypto Holdings, Inc."
filed_at: "2025-09-08T23:59:59+00:00"
generated_at: "2026-05-17T07:32:15.421897+00:00"
event_type: "regulatory"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Qualigen gets final Nasdaq extension to prove equity compliance by Nov 15 after negative equity

## Summary
- Nasdaq Panel granted final exception to demonstrate compliance with $2.5M equity rule by Nov 15, 2025; no further extensions.
- As of June 30, 2025, stockholders' equity was approximately negative $1.6 million, failing the requirement.
- Company completed $4.3M Series A-3 Preferred private placement on July 28, but Panel excluded it from July 28 compliance date.
- Amendment to Marizyme promissory note reduced collateral charge, increasing equity by over $600,000.
- Company is current on SEC filings and regained compliance with Nasdaq Periodic Filing Rule.

## SEC filing metadata
- accession: 0001641172-25-026864
- form_type: 8-K
- ticker: AIXC
- cik: 0001460702
- company_name: AIxCrypto Holdings, Inc.
- filed_at: 2025-09-08T23:59:59+00:00
- event_type: regulatory
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 3.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1460702/000164117225026864/0001641172-25-026864-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1460702/000164117225026864/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001641172-25-026864
- JSON: https://secwatch.observer/filing/0001641172-25-026864.json
- Plain text: https://secwatch.observer/filing/0001641172-25-026864.txt

## Key facts
- Listing & Compliance Notices
  AIxCrypto Holdings, Inc. received a nasdaq extension granted notice regarding stockholders equity (rules 5550(b)(1)).
  - Exchange: nasdaq
  - Notice: extension granted
  - Deficiency: stockholders equity
  - Rules: 5550(b)(1)
  source text: September 4, 2025, Qualigen Therapeutics, Inc. (the “Company”) received a written decision (the “Decision Letter”) from the Nasdaq Hearings Panel (the “Panel”) in response to the Company’s August 19, 2025 update and request for a compliance determination with respect to the Panel’s July 24, 2025 decision, as amended. As previously disclosed, on July 24, 2025, the Panel granted the Company an exception to remain listed on The Nasdaq Capital Market, conditioned on demonstrating compliance with Nasdaq Listing Rule 5550(b)(1) (the “Equity Rule”), which requires companies to maintain stockholders’
  evidence_url: https://www.sec.gov/Archives/edgar/data/1460702/000164117225026864/0001641172-25-026864-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.